Role of statins in clinical evolution of octogenarian patients admitted due to COVID-19
Copyright © 2023 Elsevier España, S.L.U. All rights reserved..
INTRODUCTION AND OBJECTIVES: coronavirus disease 2019 (COVID-19) causes high mortality in elderly patients. Some studies have shown a benefit of statin treatment in the evolution of this disease. Since there are no similar publications in this population group, the aim of this study is to analyze in-hospital mortality in relation to preadmission treatment with statins in an exclusively elderly population of octogenarian patients.
MATERIALS AND METHODS: A single-center retrospective cohort study was performed including a total of 258 patients ≥80 years with hospital admission for confirmed COVID-19 between March 1 and May 31, 2020. They were divided into two groups: taking statins prior to admission (n=129) or not (n=129).
RESULTS: In-hospital mortality due to COVID-19 in patients ≥80 years (86.13±4.40) during the first wave was 35.7% (95% CI: 30.1-41.7%). Mortality in patients previously taking statins was 25.6% while in those not taking statins was 45.7%. Female sex (RR 0.62 [0.44-0.89]; p=0.008), diabetes (RR 0.61 [0.41-0.92]; p=0.017) and pre-admission treatment with statins (RR 0.58 95% CI [0.41-0.83]; p=0.003) were associated with lower in-hospital mortality. Severe lung involvement was associated with increased in-hospital mortality (RR 1.45 95% CI [1.04-2.03]; p=0.028). Hypertension, obesity, age, cardiovascular disease and a higher Charlson index did not, however, show influence on in-hospital mortality.
CONCLUSIONS: In octogenarian patients treated with statins prior to admission for COVID-19 in the first wave, lower in-hospital mortality was observed.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:161 |
|---|---|
| Enthalten in: |
Medicina clinica - 161(2023), 4 vom: 25. Aug., Seite 147-153 |
| Sprache: |
Englisch |
|---|
| Weiterer Titel: |
Papel de las estatinas en la evolución clínica de los pacientes octogenarios ingresados por COVID-19 |
|---|
| Beteiligte Personen: |
Jiménez Martínez, Carla [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 16.08.2023 Date Revised 16.08.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.medcli.2023.03.027 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM357978013 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM357978013 | ||
| 003 | DE-627 | ||
| 005 | 20231226073747.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.medcli.2023.03.027 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1193.xml |
| 035 | |a (DE-627)NLM357978013 | ||
| 035 | |a (NLM)37296046 | ||
| 035 | |a (PII)S0025-7753(23)00174-4 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Jiménez Martínez, Carla |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Role of statins in clinical evolution of octogenarian patients admitted due to COVID-19 |
| 246 | 3 | 3 | |a Papel de las estatinas en la evolución clínica de los pacientes octogenarios ingresados por COVID-19 |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.08.2023 | ||
| 500 | |a Date Revised 16.08.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Elsevier España, S.L.U. All rights reserved. | ||
| 520 | |a INTRODUCTION AND OBJECTIVES: coronavirus disease 2019 (COVID-19) causes high mortality in elderly patients. Some studies have shown a benefit of statin treatment in the evolution of this disease. Since there are no similar publications in this population group, the aim of this study is to analyze in-hospital mortality in relation to preadmission treatment with statins in an exclusively elderly population of octogenarian patients | ||
| 520 | |a MATERIALS AND METHODS: A single-center retrospective cohort study was performed including a total of 258 patients ≥80 years with hospital admission for confirmed COVID-19 between March 1 and May 31, 2020. They were divided into two groups: taking statins prior to admission (n=129) or not (n=129) | ||
| 520 | |a RESULTS: In-hospital mortality due to COVID-19 in patients ≥80 years (86.13±4.40) during the first wave was 35.7% (95% CI: 30.1-41.7%). Mortality in patients previously taking statins was 25.6% while in those not taking statins was 45.7%. Female sex (RR 0.62 [0.44-0.89]; p=0.008), diabetes (RR 0.61 [0.41-0.92]; p=0.017) and pre-admission treatment with statins (RR 0.58 95% CI [0.41-0.83]; p=0.003) were associated with lower in-hospital mortality. Severe lung involvement was associated with increased in-hospital mortality (RR 1.45 95% CI [1.04-2.03]; p=0.028). Hypertension, obesity, age, cardiovascular disease and a higher Charlson index did not, however, show influence on in-hospital mortality | ||
| 520 | |a CONCLUSIONS: In octogenarian patients treated with statins prior to admission for COVID-19 in the first wave, lower in-hospital mortality was observed | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Aged | |
| 650 | 4 | |a Anciano | |
| 650 | 4 | |a Anciano de 80 o más años | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Estatinas | |
| 650 | 4 | |a Hipolipemiantes | |
| 650 | 4 | |a Hospital mortality | |
| 650 | 4 | |a Hydroxymethylglutaryl-CoA reductase inhibitors | |
| 650 | 4 | |a Hypolipidemic agents | |
| 650 | 4 | |a Inhibidores de hidroximetilglutaril-CoA reductasas | |
| 650 | 4 | |a Lipid lower agents | |
| 650 | 4 | |a Mortalidad | |
| 650 | 4 | |a Mortalidad hospitalaria | |
| 650 | 4 | |a Mortality | |
| 650 | 4 | |a Octogenarians | |
| 650 | 4 | |a Octogenarios | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a Statins | |
| 650 | 7 | |a Hydroxymethylglutaryl-CoA Reductase Inhibitors |2 NLM | |
| 700 | 1 | |a Espejo Bares, Victoria |e verfasserin |4 aut | |
| 700 | 1 | |a Artiaga de la Barrera, Verónica |e verfasserin |4 aut | |
| 700 | 1 | |a Marco Quirós, Cecilia |e verfasserin |4 aut | |
| 700 | 1 | |a Pérez Fernández, Elia |e verfasserin |4 aut | |
| 700 | 1 | |a Luz Martínez Mas, Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Botas Rodríguez, Javier |e verfasserin |4 aut | |
| 700 | 0 | |a en representación del grupo de estudio |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Medicina clinica |d 1948 |g 161(2023), 4 vom: 25. Aug., Seite 147-153 |w (DE-627)NLM000359017 |x 1578-8989 |7 nnns |
| 773 | 1 | 8 | |g volume:161 |g year:2023 |g number:4 |g day:25 |g month:08 |g pages:147-153 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.medcli.2023.03.027 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 161 |j 2023 |e 4 |b 25 |c 08 |h 147-153 | ||